- Home
- ZBIO vs RGNX Comparison
ZBIO vs RGNX Comparison
Compare ZBIO & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBIO
- RGNX
- Stock Information
- Founded
- ZBIO 2019
- RGNX 2008
- Country
- ZBIO United States
- RGNX United States
- Employees
- ZBIO N/A
- RGNX N/A
- Industry
- ZBIO
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZBIO
- RGNX Health Care
- Exchange
- ZBIO NYSE
- RGNX Nasdaq
- Market Cap
- ZBIO 389.2M
- RGNX 424.8M
- IPO Year
- ZBIO 2024
- RGNX 2015
- Fundamental
- Price
- ZBIO $12.15
- RGNX $8.34
- Analyst Decision
- ZBIO Strong Buy
- RGNX Strong Buy
- Analyst Count
- ZBIO 7
- RGNX 8
- Target Price
- ZBIO $32.29
- RGNX $31.75
- AVG Volume (30 Days)
- ZBIO 189.4K
- RGNX 769.5K
- Earning Date
- ZBIO 08-16-2025
- RGNX 07-31-2025
- Dividend Yield
- ZBIO N/A
- RGNX N/A
- EPS Growth
- ZBIO N/A
- RGNX N/A
- EPS
- ZBIO N/A
- RGNX N/A
- Revenue
- ZBIO $15,000,000.00
- RGNX $156,718,000.00
- Revenue This Year
- ZBIO $165.20
- RGNX $327.08
- Revenue Next Year
- ZBIO $63.75
- RGNX N/A
- P/E Ratio
- ZBIO N/A
- RGNX N/A
- Revenue Growth
- ZBIO N/A
- RGNX 80.70
- 52 Week Low
- ZBIO $5.83
- RGNX $5.04
- 52 Week High
- ZBIO $26.25
- RGNX $15.36
- Technical
- Relative Strength Index (RSI)
- ZBIO N/A
- RGNX 47.68
- Support Level
- ZBIO N/A
- RGNX $8.51
- Resistance Level
- ZBIO N/A
- RGNX $9.27
- Average True Range (ATR)
- ZBIO 0.00
- RGNX 0.50
- MACD
- ZBIO 0.00
- RGNX 0.02
- Stochastic Oscillator
- ZBIO 0.00
- RGNX 50.37
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.